ClinicalTrials.gg
RecruitingNCT06421506Updated Aug 6, 2026

Less Invasive Surfactant Administration in Late Preterm or Early Term Born Infants

An interventional study of Less invasive surfactant administration during high flow nasal cannula treatment in Respiratory Distress Syndrome, Preterm Pregnancy and Surfactant Deficiency Syndrome Neonatal, sponsored by King's College Hospital NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 34 Weeks to 38 Weeks. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by King's College Hospital NHS Trust · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
245
Allocation
Non-randomized
Ages
34 Weeks to 38 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom — 10 open to participants now, 13 under way, 3 of them phase 3. Respiratory Distress Syndrome · United Kingdom.

Planned enrollment
11th of 31
245 · median 90
Started
2024
with 1 other
No phase
10 of 47
2 open now
Primary completion
2027-09
later than 8 of 12 live
Registered
42nd of 47
by date

Among the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, this one is the 11th largest by planned enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2024, is one of 10 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 42nd registered.

Respiratory Distress Syndrome

1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

10 of the 47 studies in Respiratory Distress Syndrome with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.

This study: 34 Weeks to 38 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Respiratory Distress Syndrome with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to see if giving less invasive surfactant administration (LISA) during high-flow nasal cannula (HFNC) oxygen treatment reduces the need for invasive ventilation in babies with breathing problems born 2-6 weeks early.

Less invasive surfactant administration is where surfactant (a naturally produced substance which helps open up the tiny air sacs in the lungs making it easier for babies to breathe) is given into the lungs by putting a small tube into the windpipe through the mouth whilst the baby is awake. The surfactant is given slowly and breathed in.

High flow nasal cannula is a form of non-invasive support where a machine delivers warmed, moist oxygen and air through short tubes in the nose.

The investigators will be assessing whether a lower percentage of neonates need invasive ventilation within 72 hrs from birth when they have had LISA during HFNC treatment, compared to when they don't receive this treatment.

The investigators will also be looking at the length of neonatal unit stay and the cost of the stay. The investigators will also be measuring the lung function of the babies before and after they receive LISA.

Read the detailed description

This study is looking at babies born 2- 6 weeks early who have breathing problems soon after birth. Some babies need to go onto a breathing machine (ventilator) or require 'non-invasive' breathing support. Either a machine delivers warmed, moist oxygen + air through short tubes in the nose (humidified high flow nasal cannula, HHFNC) or a machine delivers oxygen and air via a small mask which fits over the nose (continuous positive airway pressure, CPAP). Mechanical ventilation via a ventilator, although life-saving, can cause problems such as infection and lung injury and, therefore, whenever possible baby's breathing is supported with 'non-invasive' methods. The use of CPAP in more mature babies may also cause discomfort or lung collapse, whereas use of HHFNC may avoid those problems. The lungs of healthy full-term babies naturally produce a substance called surfactant that helps open up the tiny air sacs in the lungs and makes it easier for them to breathe. Babies born early or those with problems at birth, do not have enough of their own surfactant or it does not work properly, causing difficulty in taking in oxygen. A natural, animal-derived surfactant medication can be given into the lungs, using a small tube put into the windpipe through the mouth. This is done routinely in ventilated babies born prematurely. More recently, a technique called 'Less invasive surfactant administration (LISA)' has been developed that allows us to give surfactant to babies who are receiving 'non-invasive' breathing support (ie HHFNC) and, thus, avoiding the complications related to mechanical ventilation. A small tube is passed into the windpipe whilst the baby is awake and breathing (supported on HHFNC or CPAP) and the surfactant is slowly given and breathed into the lungs. At the moment, there have been no research studies assessing the use of LISA in more mature infants receiving HHFNC as 'non-invasive' respiratory support.

In this study the investigators want to determine if in babies born between 34 and 38+6 weeks gestation who have breathing problems and receive HHFNC oxygen treatment with LISA within 24 hours of birth will reduce the need for mechanical ventilation. The investigators will also be looking a the length on neonatal unit stay, and the cost of the stay. Lung function of the babies before and after they receive LISA will be measured.

There will be no change in the management of babies taking part in the study. Use of HHFNC, administration of LISA and respiratory monitoring is all part of routine practice. The investigators are asking for consent to analyse the routine monitoring that will be undertaken before, during and after the surfactant administration and follow up on the outcome of the baby after they have had the LISA procedure.

Surfactant is routinely used in babies and there are no extra risks from taking part in this study. HHFNC is routinely used to support babies of this gestational age who require respiratory support. There are no known or expected risks from using HHFNC with LISA but as of yet there have been no studies using this combination.

Giving surfactant may help to avoid mechanical ventilation and its side effects, but this has not been studied before in these gestational ages, hence the need for this study. Theoretically giving surfactant with HHFNC should aid even distribution of surfactant throughout the lungs whilst protecting the lungs from potential damage caused by other forms of non-invasive support such as CPAP but again there is not yet evidence supporting this.

The study will be running at King's College Hospital on the Neonatal Intensive Care Unit at the Denmark hill site and at the Local Neonatal Unit at the Princess Royal Hospital site. The study has received ethical approval and is due to commence imminently (May 2024). The study is aiming to recruit 245 patients which is estimated to take 2yrs and 4 months.

The study is funded by Chiesi Limited. The chief investigator for the study is Theodore Dassios: theodore.dassios@kcl.ac.uk

03

Conditions studied

  • Respiratory Distress Syndrome
  • Preterm Pregnancy
  • Surfactant Deficiency Syndrome Neonatal
04

Who can participate

Ages eligible
34 Weeks to 38 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Infants born at 34+0 to 38+6 weeks of gestation, requiring resuscitation at birth, but who achieve regular spontaneous breathing and have a heart rate over 100 beats per minute while receiving non-invasive support.
  • Infants enrolled in the Surfon trial, born at 34+0 to 38+6 weeks of gestation, who are less than or equal to 24 hours old and exhibit signs of respiratory distress, defined as an FiO2 greater or equal to 0.30 but less than 0.45 needed to maintain an SpO2 greater than or equal to 92% or a work of breathing regardless of the FiO2 and a clinical decision to provide non-invasive respiratory support.

Exclusion criteria

Exclusion Criteria:

  • Infants requiring intubation at birth
  • Infants with severe congenital anomalies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
245 participants (estimated)

Study arms

  • Experimental
    Neonates given LISA during HFNC treatment

    Infants between 34-38+6 weeks gestation will receive surfactant via less invasive administration whilst on high flow nasal cannula oxygen treatment. They will have respiratory function monitoring before and after LISA.

    Procedure: Less invasive surfactant administration during high flow nasal cannula treatment

  • No intervention
    Neonates not given LISA

    Infants between 34-38+6 will receive routine care and will not receive surfactant unless intubated.

Interventions

  • ProcedureLess invasive surfactant administration during high flow nasal cannula treatment

    Surfactant distilled through a small tube inserted into the windpipe via the mouth whilst the baby is awake and supported with HFNC.

06

What researchers measure

Primary outcomes

  1. The percentage of neonates needing invasive ventilation within 72 hours from birth

    The percentage of babies requiring more respiratory support and therefore needing invasive ventilation within 72 hrs from birth. The percentage from the intervention group will be compared with the control group

    Time frame: 72 hours from birth

Secondary outcomes

  1. The length of neonatal unit stay

    The duration of stay on the neonatal unit will be compared between the babies receiving the intervention, and those who are not.

    Time frame: The length of time the neonate is in hospital, up to 20 weeks

  2. The cost of stay as estimated via standard NHS tariffs according to level of care

    Standard NHS tariffs will be used to calculate the total cost of the stay for the babies in the intervention vs control group.

    Time frame: The length of time the neonate is in hospital, up to 20 weeks

  3. The lung function parameters two minutes before and two minutes after the administration of LISA

    The following lung function parameter: tidal volume will be measured for all babies receiving LISA.

    Time frame: The first 24 hours of life

  4. The lung function parameters two minutes before and two minutes after the administration of LISA

    The following lung function parameter: respiratory rate will be measured for all babies receiving LISA.

    Time frame: The first 24 hours of life

  5. The lung function parameters two minutes before and two minutes after the administration of LISA

    The following lung function parameter: fraction of inspired oxygen (FiO2) will be measured for all babies receiving LISA.

    Time frame: The first 24 hours of life

  6. The lung function parameters two minutes before and two minutes after the administration of LISA

    The following lung function parameter: End Tidal CO2 (ETCO2) will be measured for all babies receiving LISA.

    Time frame: The first 24 hours of life

  7. The lung function parameters two minutes before and two minutes after the administration of LISA

    The following lung function parameter: ratio of oxygen saturations/ fractions of inspired oxygen (SpO2/ FiO2 ratio) will be measured for all babies receiving LISA.

    Time frame: The first 24 hours of life

  8. The SpO2/FiO2 ratio will be measured two hours after LISA administration

    Lung function parameter: ratio SpO2/FiO2 will be measured two hours after LISA administration for all babies receiving LISA

    Time frame: The first 24 hours of life

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Herting E, Hartel C, Gopel W. Less invasive surfactant administration (LISA): chances and limitations. Arch Dis Child Fetal Neonatal Ed. 2019 Nov;104(6):F655-F659. doi: 10.1136/archdischild-2018-316557. Epub 2019 Jul 11. PubMed 31296694 ↗
  • Shetty S, Egan H, Cornuaud P, Kulkarni A, Duffy D, Greenough A. Less Invasive Surfactant Administration in Very Prematurely Born Infants. AJP Rep. 2021 Jul;11(3):e119-e122. doi: 10.1055/s-0041-1735632. Epub 2021 Sep 22. PubMed 34567837 ↗
  • Smithhart W, Wyckoff MH, Kapadia V, Jaleel M, Kakkilaya V, Brown LS, Nelson DB, Brion LP. Delivery Room Continuous Positive Airway Pressure and Pneumothorax. Pediatrics. 2019 Sep;144(3):e20190756. doi: 10.1542/peds.2019-0756. Epub 2019 Aug 9. PubMed 31399490 ↗
  • Spence KL, Murphy D, Kilian C, McGonigle R, Kilani RA. High-flow nasal cannula as a device to provide continuous positive airway pressure in infants. J Perinatol. 2007 Dec;27(12):772-5. doi: 10.1038/sj.jp.7211828. Epub 2007 Aug 30. PubMed 17762844 ↗
  • Jeffreys E, Jenkinson A, Kaltsogianni O, Harris C, Bhat R, Dassios T, Greenough A. Does less invasive surfactant administration during high-flow nasal cannula oxygen treatment reduce the need for invasive ventilation in late preterm and early term born infants with respiratory distress? A study protocol for a single-centre study with a treatment and control arm. BMJ Open. 2025 Jun 23;15(6):e089399. doi: 10.1136/bmjopen-2024-089399. PubMed 40550714 ↗

Individual participant data

Plan to share: No — The General Data Protection Regulation and Data Protection Act 2018 will be adhered to. Data will be anonymised before being entered into a secure database. Each participant will be issued a unique study identifier number when enrolled and this will be used on all data collection forms. Patient paper data will be stored in a locked filing cabinet in a room that is only accessible to the research team and that is based on the Neonatal Intensive Care Unit facilities at King's College Hospital. De-identified electronic patient data will be stored on encrypted computers or memory stick devices. On completion, the data will be analysed and a final report prepared that could be accessed via the sponsor. The study will be presented at research meetings at King's College Hospital. Anonymised study data will be presented at conferences and published by the investigators in peer reviewed journals. Participants will be notified of the outcome of the study via provision of the publication.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Sep 2027, 40 months after the start.

Of 266 non-industry interventional studies with no phase under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 40 months is above that.

Counting every sponsor, half of 273 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2024
First posted
May 20, 2024
StartActual
May 8, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06421506
Collaborators
Chiesi Limited
Responsible party
Sponsor
First posted
May 20, 2024
Start date
May 8, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 6, 2026

Study contacts

Eleanor Jeffreys, MBBS
Contact
eleanor.jeffreys@nhs.net
+447519 974813
Theodore Dassios, PHD
principal investigator · King's College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion